SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (3)7/11/2006 3:50:52 PM
From: zeta1961  Read Replies (1) | Respond to of 285
 
Dr. P, thanks for your summary..I agree on every point!..how about that?!..I'm sorry to say that I've not kept up with this one..what is the bottle-neck about?

No rush..and thanx in advance..
Elisabeth



To: dr.praveen who wrote (3)7/27/2006 11:14:34 AM
From: dr.praveen  Respond to of 285
 
AZN has dropped development of AZD 7009 for atrial fibrillation

Navid Malik at Collins Stewart said the decision to end development of an intravenous form of experimental drug AZD 7009 for atrial fibrallation also knocked sentiment.

<My previous post has a little info on SE of AZD 7009. Waiting for the 600mg oral dose results in September from Cardiome>

yahoo.reuters.com.

Regards,
Praveen


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News